Bacteriophage Project
Antibiotic-Resistant Bacterial Infections (e.g., nosocomial infections)
Research/Pre-clinicalActive
Key Facts
Indication
Antibiotic-Resistant Bacterial Infections (e.g., nosocomial infections)
Phase
Research/Pre-clinical
Status
Active
Company
About Fluart Innovative Vaccines
Fluart Innovative Vaccines is a pioneering Hungarian biotech with over 33 years of expertise in influenza vaccine development and manufacturing, having produced over 35 million doses. It leverages its GMP-certified facilities to provide full-spectrum CDMO services while advancing an innovative pipeline that includes next-generation influenza vaccines and bacteriophage therapies for antibiotic-resistant infections. The company is a recognized player in the global vaccine ecosystem, collaborating with international health organizations like the WHO and CDC.
View full company profile